The results of this study suggest that SGLT2 inhibitors might have an inadequate effect on atherogenic lipid profiles or inflammatory markers in patients with a low risk of cardiovascular disease (including well or appropriate control of glucose levels, obesity, and fatty liver). Here, SLC5A2 is linked to cardiovascular disorder.